Logo
x

Search

Subscribe Now

Approval 

Novartis’ Pluvicto (177Lu-PSMA-617) Received the US FDA’s Approval as the First Targeted Radioligand Therapy for Progressive, PSMA Positive mCRPC

Novartis’ Pluvicto (177Lu-PSMA-617) Received the US FDA’s Approval as the First Targeted Radioligand Therapy for Progressive, PSMA...

  • March 23, 2022
Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial Carcinoma

Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial C...

  • September 27, 2021
Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis

Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis

  • September 22, 2021
Exelixis' Cabometyx (cabozantinib) Receives the US FDA's Approval for the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer

Exelixis' Cabometyx (cabozantinib) Receives the US FDA's Approval for the Treatment of Locally Advanced or Metastatic Differentiat...

  • September 20, 2021
Amgen's Lumakras (sotorasib) Receives Health Canada's Approval for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Amgen's Lumakras (sotorasib) Receives Health Canada's Approval for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell...

  • September 14, 2021
Impel NeuroPharma's Trudhesa (dihydroergotamine mesylate) Nasal Spray Receives the US FDA's Approval for the Treatment of Migraine

Impel NeuroPharma's Trudhesa (dihydroergotamine mesylate) Nasal Spray Receives the US FDA's Approval for the Treatment of Migraine

  • September 7, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.